Pfizer Inc. PFE
27.40 USD -0.14 (-0.51%)
Regular-session close
27.44 +0.04 +0.15%
After hours · Nov 20, 7:52 PM ET
27.36 Day range 28.11
23.67 52-week range 30.79
- YTD
- +10.04%
- 1 year
- +12.30%
News
fool.com Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027? Johnson & Johnson maintains a diversified business model balancing pharmaceutical innovation with a massive medical technology segment. Pfizer is undergoing a significant transition by investing…
fool.com Pfizer's Launched and Acquired Drugs Grew 32% in Q3 — and 3 Other Reasons to Buy the Stock Before 2027 Pfizer is a well-respected drugmaker facing typical industry headwinds. The company is financially strong, and new drug development is slowly gaining traction.
zacks.com Lilly vs. Pfizer: Which Drugmaker Has Stronger Growth Prospects? Lilly and Pfizer offer contrasting growth stories driven by blockbuster drugs, expanding pipelines and strategic investments.
247wallst.com 5 High-Yield Dividend Stocks Retirees Can Buy for Under $50 a Share Retirees hunting for income often reach for low-priced shares, but a share price only sets the cost of a single share. Valuation multiples, payout coverage and balance sheet strength decide whether a…
zacks.com Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
247wallst.com 4 Dividend Stocks Wall Street Gave Up On With Balance Sheets Built to Recover When a stock falls out of favor, the balance sheet decides what happens to your income. A company with manageable debt and steady cash flow can keep paying shareholders while it repairs the business.
247wallst.com Pfizer Yields 6.25%. These 3 Dividend Stocks Pay More Than a 1-Year Treasury Bill A risk-free Treasury bill sounds hard to beat, yet three dividend payers in healthcare, tobacco, and pipelines offer more income. Each one also hides a risk that could turn a fat yield into a costly…
247wallst.com 4 Yield Traps Paying Over 6% That Retirees Should Watch Out For One of these high yields keeps paying monthly while its book value shrinks, and another looks safe until you check the debt. Before trusting a big payout in retirement, see which four stocks fail the…
zacks.com PFE Inks $2.6B Licensing Deal With Chinese Biotech for CAR-T Therapies Pfizer's $2.6 billion Starna deal adds three investigational CAR-T programs, strengthening its push into next-generation autoimmune treatments.
zacks.com Can New Products and Acquisitions Revive Pfizer's Growth Story? PFE's new launches and acquisitions are reshaping its business, supporting its ambitions to return to growth from 2029.
247wallst.com Forget JEPI: 4 High-Yield Dividend Stocks Retirees Should Own Instead JEPI's monthly check looks generous until you notice what it quietly cost retirees in a single year. Four dividend payers trade a smaller paycheck today for raises, tax perks, and rallies you…
247wallst.com 4 S&P 500 Dividend Stocks Paying Shareholders More Than Their Free Cash Flow A fat yield looks like a gift until the cash behind it runs dry. Four household S&P 500 names are sending shareholders checks bigger than the money coming in, and one test shows which payouts may not…
fool.com Pfizer Will Pay Its 352nd Straight Quarterly Dividend on Dec. 7. Here's What It Would Take to Break the Streak. Pfizer will pay its 352nd consecutive quarterly dividend on Dec. 7, 2026. A patent cliff, a cash-draining acquisition, and major clinical setbacks could threaten the dividend, but all three would…
benzinga.com Pfizer Strikes Multibillion-Dollar Deal to Take on Autoimmune Diseases Pfizer signs up to $2.63B licensing deal with Starna Therapeutics for in vivo CAR-T autoimmune therapies, paying $330M upfront.
seekingalpha.com Pfizer: The Patent Cliff Fears Are Overblown Pfizer Inc., a Big Pharma player offering a 5.96% dividend yield, remains a controversial choice among long-term retail investors. Most concerns reflect PFE's upcoming patent expiration cycle, which…
247wallst.com 4 Dividend Stocks Yielding Over 6% That Fit a Roth IRA Four stocks paying over 6% can quietly hand the IRS thousands every year, and one of them gets taxed far harder than the rest. Find out which holding belongs in a Roth first and why the gap keeps…
247wallst.com 3 High-Yield Dividend Stocks Down Nearly 30% or More in 5 Years Three famous dividend payers have lost a big chunk of their value since 2020, and two already slashed their payouts. Before chasing the fat yields, income investors should ask which of these…benzinga.com Pfizer Signs Exclusive Licensing Agreement With Starna Therapeutics To Commercialize Three Pre-IND In Vivo Chimeric Antigen Receptor T-Cell Programs Outside Of China For $330M Up Front And Up To $2.3B In Milestones Deal Terms and Financial DetailsStarna will receive an upfront payment of $330 million.Starna is eligible to receive up to $2.3 billion in milestone payments associated with certain development and…
businesswire.com Pfizer Enters into Exclusive Licensing Agreement with Starna Therapeutics for Autoimmune Diseases NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that it entered into an exclusive licensing agreement with Starna Therapeutics, a biotechnology company developing RNA medicines…
seekingalpha.com Pfizer: Strong Growth Momentum And Attractive Valuation Support A Strong Buy Pfizer remains a Strong Buy: improved gross margin, accelerating launched and acquired products, and raised guidance support the thesis. Q3 revenue reached $16.58B, beating by $700M; launched and…
247wallst.com Wall Street Forgot These 3 Dividend Stocks — Now They Pay Over 5% Income investors tend to crowd into whatever is popular, leaving solid payers ignored. The three stocks below are in health care, telecom, and financials.
fool.com Johnson & Johnson vs. Pfizer: Consistency vs. Johnson & Johnson currently exhibits a stronger overall revenue profile than Pfizer by maintaining consistently higher absolute sales volume across every reported period. Over roughly the last eight…
247wallst.com 5 Safe High-Yield Dividend Stocks Boomers Should Buy Before Year-End Retirees heading into year-end need income that holds up through a recession, a rate shift or a bad quarter, so a high yield alone isn't enough. These five US-listed payers come from five different…
247wallst.com 5 “Forever Income” Dividend Stocks Yielding 5% and More for Boomers If you're retired and living off a portfolio, a dividend has two jobs. It has to pay enough to matter, and it has to keep paying through a full market cycle.
247wallst.com 5 Dividend Stocks Yielding Over 5% to Hide in Your Roth IRA Five high-yield payers could be quietly handing the IRS thousands of dollars every year, and two of them are taxed far more harshly than the rest. Where you park them matters more than which ones you…
247wallst.com 5 Huge Dividend Payers the IRS Leaves Alone Inside a Roth Two investors can hold the exact same five blue chip dividend stocks and still walk away with very different paychecks. The difference comes down to one account choice, and over 20 years it snowballs…
marketbeat.com Pfizer CEO Sees Growth Beyond Patent Cliff, Highlights Monthly Obesity Drug Ambitions Pfizer NYSE: PFE expects recently launched medicines and a growing pipeline to help it emerge from a period of patent expirations with high single-digit growth, CEO Albert Bourla said at the…
seekingalpha.com Pfizer Inc. (PFE) Presents at Jefferies Global Healthcare Conference 2026 Transcript Pfizer Inc. (PFE) Presents at Jefferies Global Healthcare Conference 2026 Transcriptbenzinga.com Reported November 16, Roche Receives FDA Approval For Wiserdley In Combination With Everolimus For Breast Cancer Treatment Wilserdly is the first and only next-generation all-oral SERD combination to significantly outperform standard endocrine combination in a post-CDK4/6 inhibitor setting in a head-to-head phase III…
fool.com 2 Stocks With Dividend Yields of 4% or More to Buy in November Dividend stocks are being forgotten by investors right now. Pfizer has a diversified portfolio with nice growth potential.
247wallst.com 5 Ultra-High-Yield Dividend Stocks Retirees Should Buy Before December One of these five payers yields 10% yet earned less than it paid out last quarter, while another cut no checks but froze its raise. Which income stocks truly cover their dividends, and which one…
247wallst.com $12,300 a Month in Dividends and Not One Bond: Is This Portfolio Too Good to Be True? A stock-only portfolio paying over $12,000 a month sounds like a retirement dream, but the income splits into layers with very different levels of reliability. Before you build it, you need to know…
247wallst.com How Much Does a 65-Year-Old Need Invested in Dividend Stocks to Collect $2,000 a Month? Three popular high-yield stocks promise a steady retirement paycheck, but one has a thin cash cushion and another has slashed its payout before. Which one could quietly shrink your monthly income…
benzinga.com Pfizer Pulls Menopause Hormone Therapy Premarin From Canadian Market Pfizer will stop selling Premarin cream and tablets in Canada after an internal review, adding strain to ongoing menopause drug shortages.
benzinga.com Blackstone Bankrolls Pfizer’s Weight Loss Drug Trials for Slice of Future Sales Pfizer and Blackstone Life Sciences signed a $1.5 billion deal to fund berobenatide, a monthly GLP-1 obesity drug entering 10 Phase 3 trials in 2026.
benzinga.com Eli Lilly Wins China Approval for First GLP-1 Weight-Loss Pill, Giving It First-Mover Edge In Potential $4.5 Billion Market: Report Eli Lilly wins China approval for its first GLP-1 weight-loss pill, gaining an early edge in the country's $4.5 billion market.benzinga.com Pfizer And Blackstone Life Sciences Enter Co-Funding Agreement Under Which Blackstone Will Pay Up To $1.5B Of Development Costs For Study Of Monthly GLP-1 Receptor Agonist Peptide Berobenatide Through 2028 Berobenatide is an investigational, potential first-in-class monthly GLP-1 receptor agonist peptide being studied for chronic weight management and obesity-related conditions. In exchange for the…
benzinga.com Medicus Pharma Unveils Capital Strategy Centered On Novel Cancer Pipeline Medicus Pharma advances its Pfizer-partnered cancer asset and plans a $135 million SkinJect SPAC deal while reducing quarterly operating expenses.benzinga.com Guggenheim Maintains Buy on Pfizer, Raises Price Target to $33 Guggenheim analyst Vamil Divan maintains Pfizer (NYSE:PFE) with a Buy and raises the price target from $31 to $33.
benzinga.com Scotiabank Maintains Sector Outperform on Pfizer, Raises Price Target to $35 Scotiabank analyst Louise Chen maintains Pfizer (NYSE:PFE) with a Sector Outperform and raises the price target from $33 to $35.
benzinga.com Citigroup Maintains Neutral on Pfizer, Raises Price Target to $30 Citigroup analyst Geoff Meacham maintains Pfizer (NYSE:PFE) with a Neutral and raises the price target from $27 to $30.
benzinga.com RBC Capital Maintains Sector Perform on Pfizer, Raises Price Target to $28 RBC Capital analyst Trung Huynh maintains Pfizer (NYSE:PFE) with a Sector Perform and raises the price target from $25 to $28.
benzinga.com Amazon, Pfizer, Eaton And A Financial Stock On CNBC’s ‘Final Trades’ CNBC's Final Trades: Brown picked Amazon, Lebenthal chose BlackRock, Snipe backed Eaton, and Terranova recommended Pfizer.
benzinga.com Nasdaq Jumps Over 200 Points as Chip Stocks Gain: Fear & Greed Index Remains in ‘Extreme Fear’ Zone Markets closed mixed as CNN Fear & Greed stayed at 19 (Extreme Fear); Nasdaq rose 0.83%, Dow fell, Apple dropped and Aehr surged 26%.
benzinga.com Nasdaq Surges 1%; Pfizer Posts Upbeat Q3 Earnings U.S. stocks were mixed as Nasdaq gained 1%; Pfizer beat Q3 estimates and raised 2026 guidance, while oil, gold and European shares fell.
benzinga.com Pfizer Q3 2026 Earnings Call Transcript Pfizer (NYSE:PFE) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Non-COVID Portfolio Steps Up: Pfizer Outpaces Consensus and Hikes Guidance Pfizer beats Q3 revenue and profit forecasts on oncology and non-COVID drug growth, raising its full-year 2026 sales and EPS outlook.benzinga.com Pfizer Raises FY2026 Adj EPS Guidance from $2.80-$3.00 to $2.95-$3.05 vs $2.96 Est; Raises FY2026 Sales Guidance from $60.500B-$62.500B to $62.000B-$64.000B vs $62.166B Est Pfizer (NYSE:PFE) raises FY2026 Adj EPS guidance from $2.80-$3.00 to $2.95-$3.05 vs $2.96 analyst estimate. Raises FY2026 sales outlook from $60.500 billion-$62.500 billion to $62.000 billion-$64.000…
benzinga.com Pfizer Q3 Adj. EPS $0.87 Beats $0.72 Estimate, Sales $16.583B Beat $15.872B Estimate Pfizer (NYSE:PFE) reported quarterly earnings of $0.87 per share which beat the analyst consensus estimate of $0.72 by 19.18 percent. This is unchanged from the same period last year. The company…
benzinga.com Pfizer Appoints Cecile Guegan As CFO And EVP, Effective November 1, 2026 Cecile Guegan to lead Pfizer’s financial strategy as Chief Financial Officer with over 25 years of pharmaceutical finance experiencePfizer Inc. (NYSE:PFE) today announced that its Board of Directors…
